What is claimed is:

1. Use of cells in the manufacture of a medicament for treating intracerebral hemorrhage in a subject, wherein said cells are multipotent adult progenitor cells that are not embryonic stem cells, not embryonic germ cells, and not germ cells, can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages, and are allogeneic or xenogeneic to the subject.

2. Use of cells in the manufacture of a medicament for treatingintracerebral hemorrhage in a subject, wherein said cells are multipotent adult progenitor cells that are not embryonic stem cells, not embryonic germ cells, and not germ cells, express telomerase and are allogeneic or xenogeneic to the subject.

3. Use of cells in the manufacture of a medicament for treatingintracerebral hemorrhage in a subject, wherein the cells are multipotent adult progenitor cells that are not embryonic stem cells, not embryonic germ cells, and not germ cells, are positive for oct3/4 and are allogeneic or xenogeneic to the subject.

4. Use of cells in the manufacture of a medicament for treatingintracerebral hemorrhage in a subject, wherein the cells are multipotent adult progenitor cells that are not embryonic stem cells, not embryonic germ cells, and not germ cells, undergone at least 40 cell doublings in culture prior to their use, and are allogeneic or xenogeneic to the subject.

5. The use according to any one of claims 2-4, wherein said cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages.

6. The use according to any one of claims 3-4 wherein said cells express telomerase.

7. The use according to 3, wherein said cells have undergone at least 40 doublings in culture prior to their use. B

8. The use according to claim 1 wherein said cells express telomerase and are positive for oct3/4.

9. The use according to claim 1, wherein said cells express telomerase and have undergone at least 40 doublings in culture prior to their use.

10. The use according to claim 1, wherein said cells are positive for oct3/4 and have undergone at least 40 doublings in culture prior to their use..

11. The use according to claim 1, wherein said cells express telomerase, are positive for oct3/4, and have undergone at least 40 doublings in culture prior to their use.

12. The use according to any one of claims 1-11, wherein said cells have a normal karyotype.

13. The use according to any one of claims 1-12, wherein said cells are not tumorigenic.

14. The use according to any one of claims 1-13, wherein said cells are not immunogenic in said subject.

15. The use according to any one of claims 1-14, wherein said cells can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages.

16. The use according to any one of claims 1-15, wherein said cells are mammalian cells.

17. The use according to any one of claims 1-16, wherein said cells are human cells.

18. The use according to any one of claims 1-17, wherein said cells are derived from cells isolated from any one of placental tissue, umbilical cord tissue, umbilical cord blood, bone marrow, blood, spleen tissue, thymus tissue, spinal cord tissue, adipose tissue, and liver tissue.

19. The use according to any one of claims 1-18, wherein said cells are derived from bone marrow.

20. The use according to any one of claims 1-19, wherein the subject is a human.

21. The use according to any one of claims 1-20, wherein one or more doses of 10^4 to 10^8 of said cells per kilogram of the subject's mass are used.

22. The use according to any one of claims 1-21, wherein one or more doses of 10^6 to 5×10^7 of said cells per kilogram of the subject's mass are used.

23. The use according to any one of claims 1-22, wherein an anti-microbial agent, an anti-fungal agent, an anti-viral agent or a combination thereof is used concurrently.

24. The use according to any one of claims 1-23, wherein said cells are in a formulation comprising one or more other pharmaceutically active agents.

25. The use according to any one of claims 1-24, wherein said cells are to be administered by a parenteral method, an intravenous method or a stereotactic method.

26. The use according to any one of claims 1-25, wherein said cells are to be administered by an intravenous method.

27. The use according to any one of claims 1-26, wherein said medicament is to be used without use of an adjunctive immunosuppressant.